Revolution Medicines Executives Sell Shares Under 10b5-1 Plan in August

Revolution Medicines executives executed significant stock sales under preset Rule 10b5-1 trading plans on August 21, 2026, according to filings reported by stocktitan.net.

Mark A. Goldsmith, President and CEO, exercised options for 80,000 shares at $4.73 per share and sold 86,000 common shares through multiple transactions. The weighted average sale prices ranged from approximately $206.78 to $212.74 per share. Goldsmith's holdings include 182,938 restricted stock units.

Jeffrey Todd Cislini, General Counsel, exercised options covering 56,280 shares at exercise prices of $18.56 and $21.61 per share and sold nearly 56,900 shares in several transactions at weighted average prices between $206.76 and $212.74. Cislini retains 43,514 restricted stock units.

These sales were conducted under Rule 10b5-1 trading plans adopted on May 22, 2026. Such plans allow insiders to prearrange stock transactions to avoid accusations of insider trading by specifying trades in advance.

Mark A. Goldsmith stated, "These transactions were executed pursuant to a 10b5-1 trading plan adopted by me on May 22, 2026."

Goldsmith's stock sale followed a prior June 16, 2026 transaction where he sold 10,020 shares for approximately $1.56 million. The planned August sale included shares totaling an estimated $16.9 million in market value based on prices at that time. The common stock of Revolution Medicines had 214,336,418 shares outstanding as of August 21, 2026.

Cislini also disclosed prior sales of 2,157 shares in June 2026 for $336,748.90. The planned sales under Rule 144 involved shares from restricted stock units and stock options scheduled to vest over coming months.

Jeffrey Todd Cislini confirmed, "The planned sales relate to restricted stock units and shares received upon the exercise of stock options granted by Revolution Medicines."

The sales were executed through Morgan Stanley Smith Barney LLC Executive Financial Services in New York. The filings reflect ongoing transparency and compliance with SEC regulations regarding insider stock transactions.